EIPR1: A Tumor-Suppressing Subchromosomal Transferable Fragment Candidate Gene 1 Protein as a Drug Target and Biomarker
EIPR1: A Tumor-Suppressing Subchromosomal Transferable Fragment Candidate Gene 1 Protein as a Drug Target and Biomarker
EIPR1 (Tumor-suppressing subchromosomal transferable fragment candidate gene 1) is a gene located on chromosome 1p36.2 has been identified as a potential drug target and biomarker for various diseases, including cancer. EIPR1 has unique features, such as its tumor-suppressing property and subchromosomal transferable fragment, which make it an attractive target for the development of new therapies. In this article, we will discuss the EIPR1 protein, its potential as a drug target, and its potential as a biomarker for various diseases.
Potential Drug Target
EIPR1 has been identified as a potential drug target due to its unique features. Its tumor-suppressing property makes it a potential target for cancer therapies. cancer therapies often target specific proteins that are over-expressed or mutated in tumors. EIPR1 has low expression in normal tissues and high expression in cancer cells, which makes it an attractive target for cancer therapies.
In addition to its tumor-suppressing property, EIPR1 has subchromosomal transferable fragment, which is a unique feature that has not been observed in many genes. A subchromosomal transferable fragment is a piece of DNA that is located outside the main chromosome. It can be transferred from one chromosome to another and can have unique functions. The subchromosomal transferable fragment of EIPR1 has been shown to have unique functions, such as regulating cell growth and apoptosis.
Potential Biomarker
EIPR1 has also been identified as a potential biomarker for various diseases. Its unique features, such as its tumor-suppressing property and subchromosomal transferable fragment, make it an attractive target for the development of new diagnostic tests and therapies.
One of the potential benefits of using EIPR1 as a biomarker is its ability to detect cancer at an early stage. EIPR1 has low expression in normal tissues, which makes it an attractive target for cancer diagnostics. Its subchromosomal transferable fragment has also been shown to have unique functions that can be used to detect cancer at an early stage.
Another potential benefit of using EIPR1 as a biomarker is its ability to predict the response of cancer cells to certain therapies. The tumor-suppressing property of EIPR1 and its subchromosomal transferable fragment make it an attractive target for cancer therapies. By using EIPR1 as a biomarker, researchers can determine which therapies are most effective in treating certain types of cancer.
Conclusion
EIPR1 is a unique protein with unique features, such as its tumor-suppressing property and subchromosomal transferable fragment. These features make it an attractive target for the development of new therapies, including cancer therapies. In addition to its potential as a drug target, EIPR1 has also been identified as a potential biomarker for various diseases. Further research is needed to fully understand the potential of EIPR1 as a drug target and biomarker.
Protein Name: EARP Complex And GARP Complex Interacting Protein 1
Functions: Acts as a component of endosomal retrieval machinery that is involved in protein transport from early endosomes to either recycling endosomes or the trans-Golgi network (PubMed:27440922). Mediates the recruitment of Golgi-associated retrograde protein (GARP) complex to the trans-Golgi network and controls early endosome-to-Golgi transport of internalized protein(PubMed:27440922). Promotes the recycling of internalized transferrin receptor (TFRC) to the plasma membrane through interaction with endosome-associated recycling protein (EARP) complex (PubMed:27440922). Controls proper insulin distribution and secretion, and retention of cargo in mature dense core vesicles (By similarity). Required for the stability of the endosome-associated retrograde protein (EARP) complex subunits and for proper localization and association of EARP with membranes (By similarity)
The "EIPR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIPR1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ELAC1 | ELAC2 | ELANE | ELAPOR1 | ELAPOR2 | Elastase | ELAVL1 | ELAVL2 | ELAVL3 | ELAVL4 | ELDR | ELF1 | ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2
